DDInter1763 DDInter621
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Temsirolimus {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Temsirolimus {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Felodipine
Felodipine {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Temsirolimus {u} (Compound) causes {v} (Side Effect) Abdominal distension
Abdominal distension {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Temsirolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Temsirolimus {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Temsirolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Temsirolimus {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Temsirolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Amiodarone
Amiodarone {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Valdecoxib
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Temsirolimus (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Temsirolimus (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Felodipine (Compound) and Felodipine may lead to a major life threatening interaction when taken with Edoxaban
Temsirolimus (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Temsirolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Temsirolimus (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Temsirolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Temsirolimus (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Edoxaban
Temsirolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Amiodarone (Compound) and Amiodarone may lead to a major life threatening interaction when taken with Edoxaban
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban